TOXINS 2024 Conference Program

« BACK

Wednesday, 17 January 2024
Wednesday, 17 January 2024
8:00 – 17:00 Poster Hall Setup
9:00 – 20:30 Registration Opens
18:00 – 19:30 Convention Hall I - A/B
Welcome and Opening Remarks
Lifetime Achievement Awards Presentation Ceremony
19:30 – 21:30 Convention Hall I - C/D
Welcome Reception
Poster and Exhibit Hall Open

Thursday, 18 January 2024
7:00 – 18:30 Registration/Information
7:30 – 8:30 Breakfast
Poster and Exhibit Hall Open
8:30 – 12:00 Convention Hall I - A/B
Plenary Session
Chair: David Simpson, MD (USA)
8:30 – 8:45 Opening remarks and introduction of
keynote speaker
David Simpson, MD (USA)
8:45 – 9:30 Molecular mechanisms of presynaptic nerve cell signaling in health and disease
Keynote Speaker: Nils Brose, PhD (Germany)
9:30 – 10:00 Muscle physiology
Preeti Raghavan, MD (USA)
10:00 – 10:30 Insights from dystonia: How might muscles respond to neurological diseases?
Rob Brownstone, FMedSci (UK)
10:30 – 11:00 Break
Poster and Exhibit Hall Open
11:00 – 11:30 Long-term effects at the neuromuscular junction—motor function recovery
Juan P. Henríquez, PhD (Chile)
11:30 – 12:00 An evidence-based medicine review of botulinum neurotoxin (BoNT) injections guided by ultrasound and EMG
Barbara Karp, MD (USA)
12:00 – 13:30 Lunch
12:00 – 14:00 Break
Poster and Exhibit Hall Open

Time Basic Science Track
Room I
 
Time Clinical Track 1A
Room V
 
Time Clinical Track 2A
Room III
 
Time Clinical Track 3A
Room IV
 
Time Clinical Track 4A
Convention Hall I A/B
 
Time Clinical Track 5A
Estrel A/B
 
Time Clinical Track 6A
Estrel C
 
Time Clinical Track 7A
Paris
 
14:00 – 15:30 Genetics and Evolution
Chair: Sabine Pellett, PhD (USA)
Co-Chair: Carolina Luquez, PhD (USA)
14:00 – 15:30 Focal Limb Dystonia, Tremor and Tics
Chair: David Simpson, MD (USA)
14:00 – 15:30 Aesthetics and Dermatology I
Chair: Michael Kane, MD (USA)
14:00 – 15:30 Adult Spasticity I
Chair: Alberto Esquenazi, MD (USA)
14:00 – 15:30 Migraine and Headache
Chair: Cristina Tassorelli, MD (Italy)
14:00 – 15:30 Injection Demonstration Workshop: Cervical Dystonia
Moderator: Alberto Albanese, MD (Italy)
14:00 – 15:30 Oromandibular Dystonia/Spasmodic Dysphonia
Chair: Andrew Blitzer, MD, DDS (USA)
14:00 – 15:30 Ultrasound Workshop: Lower Limb
Chair: Katharine Alter, MD (USA)
14:00 – 14:20 Ancient clostridium species and neurotoxins revealed by metagenomic analysis of human archaeological remains
Andrew C. Doxey, PhD (Canada)
14:00 – 14:25 BoNT for tics
Sarah Pirio-Richardson, MD, FAAN (USA)
14:00 – 14:25 Gender, ethnic, and age considerations for the use of neuromodulators in facial aesthetics
Patricia Ogilvie, MD (Germany)
14:00 – 14:25 Modeling long-term outcomes for BoNT-A in patients with post-stroke spasticity
Klemens Fheodoroff, MD (Austria)
14:00 – 14:25 Newer proposed mechanisms of action of BoNT-A in migraine
Rami Burstein, PhD (USA)
14:00 – 15:30 Injectors:
Urban Fietzek, MD (Germany)
Walter Raffauf, MD (Germany)
14:00 – 14:20 Spasmodic dysphonia
Andrew Blitzer, MD, DDS (USA)
14:00 – 15:30 Katharine Alter, MD (USA)
Heakyung Kim, MD (USA)
Serdar Koçer, MD (Switzerland)
Steffen Berweck, MD (Germany)
Sebastian Schroeder, MD (Germany)
Michael Munin, MD (USA)
Sophie Cho, MD (USA)
Atul Patel, MD (USA)
Panagiotis Kassavetis, MD, PhD (USA)
Yeva Fernandez, MD (USA)
14:20 – 14:40 Towards understanding the role of OrfX/P47
Maria Nowakowska, MSc (Finland)
14:25 – 14:45 Ten years of musician's dystonia: Individual responses to treatment
Michele Vecchio, MD, PhD (Italy)
14:25 – 14:50 Ptosis: What can we do about this?
Michael Kane, MD (USA)
14:25 – 14:45 Online monitoring of long-term spasticity management with BoNT-A
Alexander Geurts, MD, PhD (Netherlands)
14:25 – 14:50 Migraine and headache update
Cristina Tassorelli, MD (Italy)
14:20 – 14:40 Diagnosis, choices of muscles to be treated with BoNT, outcomes and expectations
Andrew Blitzer, MD, DDS (USA)
14:40 – 15:00 Evaluation of botulinum neurotoxin serotype F in a bivalent Bf strain isolated from an infant botulism case, 2018
Victoria Foltz, BSc (USA)
14:45 – 15:10 Essential tremor
Sanjay Pandey, MD (India)
14:50 – 15:15 Hyperhidrosis update
Marcus Naumann, MD (Germany)
14:45 – 15:10 Spasticity-related quality of life: Six dimensions instrument (SQoL-6D) in upper limb spasticity
Jorge Jacinto, MD (Portugal)
14:40 – 15:00 Motor and phonic tics
Andrew Blitzer, MD, DDS (USA)
15:00 – 15:30 Mimicking the multivalent binding of bacterial protein toxins to their cellular receptors in a native-like membrane environment
Laura-Varenne Wilk, PhD (Germany)
15:10 – 15:30 IncobotulinumtoxinA in the treatment of musician’s focal hand dystonia:
A placebo-controlled, crossover trial
David Simpson, MD (USA)
15:15 – 15:30 Panel Discussion
15:10 – 15:20 Choice of shoulder muscles for the multi-pattern treatment of upper limb spasticity with botulinum neurotoxin injections
Jörg Wissel, MD, FRCP (Germany)
14:50 – 15:30 Injection Demonstration Workshop: Migraine and Headache
Moderator: Cristina Tassorelli, MD (Italy)

Injector:
Heike Israel-Willner, MD (Germany)
15:00 – 15:20 Tongue muscles
Raymond Rosales, MD, PhD (Philippines)
15:20 – 15:30 A practical booklet for ultrasound-guided botulinum toxin injections
Stefano Carda, MD (Switzerland)
15:20 – 15:30 Panel Discussion
15:30 – 16:15 Break
Poster and Exhibit Hall Open
Educational Theatre
15:30 – 16:15 Break
Poster and Exhibit Hall Open
Educational Theatre
15:30 – 16:15 Break
Poster and Exhibit Hall Open
Educational Theatre
15:30 – 16:15 Break
Poster and Exhibit Hall Open
Educational Theatre
15:30 – 16:15 Break
Poster and Exhibit Hall Open
Educational Theatre
15:30 – 16:15 Break
Poster and Exhibit Hall Open
Educational Theatre
15:30 – 16:15 Break
Poster and Exhibit Hall Open
Educational Theatre
15:30 – 16:15 Break
Poster and Exhibit Hall Open
Educational Theatre
Time Basic Science Track
Room I
 
Time Clinical Track 1B
Room V
    Time Clinical Track 3B
Room IV
 
Time Clinical Track 4B
Convention Hall I A/B
 
Time Clinical Track 5B
Estrel A/B
 
Time Clinical Track 6B
Estrel C
 
Time Clinical Track 7B
Paris
 
16:15 – 17:45 Structural insights of BoNTs
Chair: Min Dong, PhD (USA)
Co-Chair: Andreas Rummel, PhD (Germany)
16:15 – 17:45 Pain
Chair: Bahman Jabbari, MD (USA)
16:15 – 17:45 Pediatric Spasticity (and Other Conditions for BoNT Relative to the Pediatric Patient)
Chair: Sebastian Schroeder, MD (Germany)
16:15 – 17:45 Injection Demonstration Workshop: Aesthetics and Dermatology
Moderator: Steve Yoelin, MD (USA)
Moderator: Patricia Ogilvie, MD (Germany)
16:15 – 17:45 Injection Demonstration Workshop: Oromandibular Dystonia/Hemifacial Spasm
Moderator: Andrew Blitzer, MD, DDS (USA)
16:15 – 17:45 Cervical Dystonia - Advanced Injection Techniques
Chair: Marie Vidailhet, MD (France)
16:15 – 17:45 Ultrasound Workshop: Upper Limb
Chair: Katharine Alter, MD (USA)
16:15 – 16:35 Cryo-EM structures of the 300 kDa progenitor toxin complexes of BoNT/B, BoNT/X, BoNT/Wo and PMP1
Pål Stenmark, PhD (Sweden)
16:15 – 16:45 Trigeminal neuralgia
Lars Bendtsen, MD, PhD, Dr.Med.Sci (Denmark)
16:15 – 16:45 Spasticity management with BoNT: Clinical trial update
Mark Gormley, MD (USA)
16:15 – 17:45 Injectors:
Tanja Fischer, MD (Germany)
Eric Petzold, MD (Germany)
Patricia Ogilvie, MD (Germany)
16:15 – 17:45 Injectors:
Andrea Stenner, MD (Germany)
Martina Müngersdorf, MD (Germany)
16:15 – 16:35 Functional anatomy and clinical patterns of cervical dystonia
Sherry Downie, PhD (USA)
16:15 – 17:45 Katharine Alter, MD (USA)
David Simpson, MD (USA)
Serdar Koçer, MD (Switzerland)
Steffen Berweck, MD (Germany)
Michael Munin, MD (USA)
Sophie Cho, MD (USA)
Atul Patel, MD (USA)
Yeva Fernandez, MD (USA)
16:35 – 16:55 Receptor-binding mechanism of botulinum neurotoxins
Rongsheng Jin, PhD (USA)
16:45 – 17:15 Pelvic pain
Barbara Karp, MD (USA)
16:45 – 17:15 Thinking outside of the box: Treating patients with severe disabilities and complex problems
Cindy B. Ivanhoe, MD (USA)
16:35 - 16:55 Optimizing outcomes from BoNT for cervical dystonia: The importance of guidance
Panagiotis Kassavetis, MD, PhD (USA)
16:55 – 17:15 Lessons learnt from the structural aspects of botulinum neurotoxin research so far
K. Ravi Acharya, PhD (UK)
16:55 – 17:20 Options for injecting BoNT in the longus colli and longus capitis muscles in the management of dystonic head flexion

Anterior approach
Lucy Hicklin, FRCS (UK)

Antero-lateral approach
Panagiotis Kassavetis, MD, PhD (USA)
17:15 – 17:35 Excitation-contraction-coupling inhibitors potentiate the activity of botulinum neurotoxin type A at the neuromuscular junction
Mickaël Machicoane, PhD (Switzerland)
17:15 – 17:45 BoNT for unusual pain conditions: Postherpetic neuralgia/occipital neuralgia, neuropathic pain/diabetic neuropathy
Bahman Jabbari, MD (USA)
17:15 – 17:45 Sialorrhea
Heakyung Kim, MD (USA)
17:20 - 17:35 Deep posterior muscles
Alexandre Kreisler, MD, PhD (France)
17:35 – 17:45 Structure-based design of a botulinum neurotoxin with triple receptor recognition
Geoffrey Masuyer, PhD (Sweden)
17:35 - 17:45 Panel Discussion
18:00 – 19:00 Room I
INA Business Meeting
18:00 - 19:00 Room I
INA Business Meeting
18:00 - 19:00 Room I
INA Business Meeting
18:00 - 19:00 Room I
INA Business Meeting
18:00 - 19:00 Room I
INA Business Meeting
18:00 - 19:00 Room I
INA Business Meeting
18:00 - 19:00 Room I
INA Business Meeting

Friday, 19 January 2024
7:00 – 18:30 Registration/Information
7:30 – 8:30 Breakfast
Poster and Exhibit Hall Open
8:30 – 12:00 Convention Hall I - A/B
Plenary Session
Chair: Giampietro Schiavo, PhD, FMedSci, FRSB (UK)
8:30 – 8:45 Welcome Back
Giampietro Schiavo, PhD, FMedSci, FRSB (UK)
8:45 – 9:30 The somatosensory perception of pain and temperature
Peter McNaughton, DPhil, PhD (UK)
9:30 – 10:10 Is there a role for botulinum toxin therapy in cancer patients?
Bahman Jabbari, MD (USA)
10:10 – 10:40 Break
Poster and Exhibit Hall Open
10:40 – 11:20 BoNT actions beyond neurons
Sara Marinelli, PhD (Italy)
11:20 – 12:00 The use of BoNT in patients with tremor
Mandar Jog, MD (Canada)
12:00 – 13:30 Lunch
12:00 – 14:00 Break
Poster and Exhibit Hall Open

Time Basic Science Track
Room I
 
Time Clinical Track 1A
Room III
 
Time Clinical Track 2A
Estrel C
 
Time Clinical Track 3A
Convention Hall I A/B
 
Time Clinical Track 4A
Estrel A/B
 
Time Clinical Track 5A
Room V
 
Time Clinical Track 6A
Room IV
 
Time Clinical Track 7A
Paris
 
14:00 – 15:30 Cell Biology of BoNTs
Chair: Ornella Rossetto, PhD (Italy)
Co-Chair: Giampietro Schiavo, PhD, FMedSci, FRSB (UK)
14:00 – 15:30 Aesthetics and Dermatology II
Chair: Nowell Solish, MD (Canada)
14:00 – 15:30 Adult Spasticity II
Chair: Anthony Ward, MBE, BSc, MD, FRCP (UK)
14:00 – 15:30 The Patient With Parkinson’s Disease (Multiple Conditions Treated With BoNT)
Chair: Francisco Cardoso, MD (Brazil)
14:00 – 15:30 Injection Demonstration Workshop: Pediatric Spasticity
Moderator: Steffen Berweck, MD (Germany)
  14:00 – 15:30 Blepharospasm/Meige Syndrome
Chair: Marie-Helene Marion, MD (UK)
14:00 – 15:30 Depression and Other Mental Disorders
Chair: Marc Axel Wollmer, MD (Germany)
14:00 – 15:30 Ultrasound Workshop: Head & Neck
Chair: Katharine Alter, MD (USA)
14:00 – 14:20 Decoding sneaky botulinum neurotoxin type A neuronal break-in into synaptic vesicles using super-resolution microscopy
Fred Meunier, PhD (Australia)
14:00 – 14:25 How botulinum toxin can restore a facial expression after facial palsy
Daniel Labbé, MD (France)
14:00 – 14:30 Does a diagnostic nerve block predict the outcome of botulinum toxin treatment?
Anthony Ward, MBE, BSc, MD, FRCP (UK)
14:00 – 14:20 Botulinum toxin in parkinsonian disorders
Robert Chen, MD (Canada)
14:00 – 15:30 Injector:
Christoph Hertzberg, MD (Germany)
14:00 – 14:30 Pretarsal or orbital injections? The art of eyelid watching and prevention and management of side effects post injection
Bettina Wabbels, MD (Germany)
14:00 – 14:30 Neuronal hypotheses and data on the mechanisms of action of botulinum toxin injections in psychiatric disorders
Tillmann H. C. Krüeger, MD (Germany)
14:00 – 15:30 Katharine Alter, MD (USA)
Heakyung Kim, MD (USA)
Serdar Koçer, MD (Switzerland)
Michael Munin, MD (USA)
Sophie Cho, MD (USA)
Barbara Karp, MD (USA)
Atul Patel, MD (USA)
Panagiotis Kassavetis, MD, PhD (USA)
Yeva Fernandez, MD (USA)
14:20 – 14:40 The effects of botulinum neurotoxins in the intestine in a mouse model of foodborne botulism
Ornella Rossetto, PhD (Italy)
14:25 – 14:50 Dose, duration, onset of action, and patient satisfaction: Are all botulinum toxins created equal?
Patricia Ogilvie, MD (Germany)
14:30 – 15:00 Botulinum toxin and multimodal treatments for functional recovery in post-stroke spasticity
Areerat Suputtitada, MD (Thailand)
14:20 – 14:40 Sialorrhea
Anna Rita Bentivoglio, MD, PhD (Italy)
14:30 – 15:00 Challenges in the treatment of Meige syndrome
Marie-Helene Marion, MD (UK)
14:30 – 15:00 Botulinum toxin as a treatment for depression – current data situation
Marc Axel Wollmer, MD (Germany)
14:40 – 15:00 Elongated iBoNT: A new botulinum neurotoxin construct for treatment of chronic pain
Charlotte Leese, PhD (UK)
14:50 – 15:05 Reversing muscle weakness caused by botulinum neurotoxin in the glabellar region: A proof-of-concept study
Steve Yoelin, MD (USA)
14:40 – 15:00 Tremor
Shivam Mittal, MD (United Arab Emirates)
15:00 – 15:20 Botulinum neurotoxin type A hijacks a heterotrimeric plasma membrane complex to intoxicate neurons
Merja Joensuu, PhD (Australia)
15:05 – 15:30 Neuromodulators from around the world: What’s here and what’s to come
Nowell Solish, MD (Canada)
15:00 – 15:30 Botulinum toxin treatment trends in patients with spasticity: A population-based study from France
Djamel Bensmail, MD, PhD (France)
15:00 – 15:20 BoNT in the management of bladder dysfunction in patients post stroke or with Parkinson's disease
Dudley Robinson, MBBS, MD, FRCOG (UK)
15:00 – 15:15 Treatment of blepharospasm in progressive supranuclear palsy with botulinumtoxin: A retrospective comparative study
Lejla Paracka, MD (Germany)
15:00 – 15:30 OnabotulinumtoxinA in resistant depression: A new paradigm comparing two facial injection sites (OnaDep study)
Danièle Ranoux, MD (France)
15:20 – 15:30 Botulinum neurotoxin type DC (BoNT/DC) blocks melanocyte melanogenesis
Birgitte Sondergaard, PhD (USA)
15:20 – 15:30 Panel Discussion
  
15:15 – 15:30 Botulinum neurotoxin treatment combined with motor learning exercises for Pisa syndrome in Parkinson’s disease – a case study
Anna Castagna, MD (Italy)
15:30 – 16:15 Break
Poster and Exhibit Hall Open
Educational Theatre
15:30 – 16:15 Break
Poster and Exhibit Hall Open
Educational Theatre
15:30 – 16:15 Break
Poster and Exhibit Hall Open
Educational Theatre
15:30 – 16:15 Break
Poster and Exhibit Hall Open
Educational Theatre
15:30 – 16:15 Break
Poster and Exhibit Hall Open
Educational Theatre
15:30 – 16:15 Break
Poster and Exhibit Hall Open
Educational Theatre
15:30 – 16:15 Break
Poster and Exhibit Hall Open
Educational Theatre
15:30 – 16:15 Break
Poster and Exhibit Hall Open
Educational Theatre
Time Basic Science Track
Room I
 
 Time Clinical Track 2B
Estrel C
Time Clinical Track 3B
Convention Hall I A/B
 
Time Clinical Track 4B
Estrel A/B
 
Time Clinical Track 5B
Room V
Time Clinical Track 6B
Room IV
Time Clinical Track 7B
Paris
 
16:15 – 17:45 Toxin Detection and Countermeasures
Chair: Suzy Kalb, PhD (USA)
Co-Chair: Patrick McNutt, PhD (USA)
16:15 – 17:45 Hot Topics
Chair: Alberto Albanese, MD (Italy)
16:15 – 17:45 Injection Demonstration Workshop: Patients With Parkinson’s Disease, Task-Specific/Focal Limb Dystonias
Moderator: Robert Chen, MD (Canada)
16:15 – 17:45 Injection Demonstration Workshop:
Adult Spasticity
Moderator: Chris Boulias, MD, PhD (Canada)
16:15 – 17:45 Use of BoNTs in Urology
Chair: Dudley Robinson, MBBS, MD, FRCOG (UK)
16:15 – 17:45 Cervical Dystonia Issues and Insights
Chair: Ryuji Kaji, MD (Japan)
16:15 – 17:45 Ultrasound Workshop: Head & Neck and Upper/Lower Limb
Chair: Katharine Alter, MD (USA)
16:15 – 16.35 Laboratory confirmation during a large cross-border outbreak of iatrogenic botulism in Europe in 2023
Martin Dorner, PhD (Germany)
16:15 – 16:45 Challenges in BoNT adherence: Impact of goal-setting, financial barriers, clinic logistics
Atul Patel, MD (USA)
16:15 – 17:45 Injectors:
David Weise, MD (Germany)
16:15 – 17:45 Injectors:
Tobias Bäumer, MD (Germany)
Jörg Wissel, MD, FRCP (Germany)
16:15 – 16.45 Mechanism of action in the bladder (motor & sensory)
Christopher Chermansky, MD (USA)
16:15 – 16.45 Botulinum toxin for the management of cervical dystonia: Why do patients discontinue treatment and how can we do better?
Jaroslaw Slawek, MD (Poland)
16:15 – 17:45 Katharine Alter, MD (USA)
Heakyung Kim, MD (USA)
Serdar Koçer, MD (Switzerland)
Steffen Berweck, MD (Germany)
Sebastian Schroeder, MD (Germany)
Michael Munin, MD (USA)
Panagiotis Kassavetis, MD, PhD (USA)
Sophie Cho, MD (USA)
Yeva Fernandez, MD (USA)
16:35 – 16:55 Detection of active BoNTs by EndoPep-MS: Is it feasible in standard microbiology laboratories?
Ilenia Drigo, PhD (Italy)
16:45 – 17:45 Prevention and management of side effects after injection of the neck and throat
Lucy Hicklin, MD (UK)
16:45 – 17:15 Management of overactive bladder: The role of botulinum toxin
Dudley Robinson, MBBS, MD, FRCOG (UK)
16:45 – 17:15 Treating pain in cervical dystonia with BoNT
Hyder (Buz) Jinnah, MD, PhD (USA)
16:55 – 17:15 X-BAT: Research on and generation of a decavalent equine antitoxin counteracting deliberate botulinum neurotoxin attacks
Emmanuel Lemichez, PhD (France)
17:15 – 17:30 Botulinum toxin type A antinociceptive activity in spinal cord and trigeminal sensory nociceptive nuclei involves central trans-synaptic transport
Dalia Nemanić, MPharm (Croatia)
17:15 – 17:45 Clinical update on the use of BoNT in urology
Christopher Chermansky, MD (USA)
17:15 – 17:45 Observations from a clinical investigator on treating cervical dystonia with a new BoNT formulation
Peter McAllister, MD (USA)
17:30 – 17:45 Facial neuromuscular junctions and selected brainstem nuclei are the targets of tetanus neurotoxin in cephalic tetanus
Federico Fabris, PhD (Italy)

Saturday, 20 January 2024
7:30 – 12:00 Information
7:30 – 9:00 Breakfast
Poster and Exhibit Hall Open
9:00 – 12:00 Convention Hall I - A/B
Plenary Session
Chair: Katharine Alter, MD (USA)
9:00 – 9:10 Welcome Back
Katharine Alter, MD (USA)
9:10 – 10:00 Questions about BoNT you were afraid to ask
Moderator: David Simpson, MD (USA)
Giampietro Schiavo, PhD, FMedSci, FRSB (UK)
Nowell Solish, MD (Canada)
Katharine Alter, MD (USA)
Francisco Cardoso, MD (Brazil)
Ornella Rossetto, PhD (Italy)
10:00 – 10:10 Best Clinical Abstract
10:10 – 10:20 Best Basic Science Abstract
10:20 – 10:50 Advances in urology: Indications, outcomes and new modes of BoNT delivery
Dudley Robinson, MBBS, MD, FRCOG (UK)
10:50 – 11:20 Long-acting botulinum toxin
Peter McAllister, MD (USA)
11:20 – 11:50 BoNT sero- and sub-type–specific neuronal selectivity
Andreas Rummel, PhD (Germany)
11:50 – 12:00 Closing Remarks
Katharine Alter, MD (USA)

« BACK